Latest Regulatory Milestones News

Orthocell has secured regulatory approval to sell its nerve repair product Remplir™ in Hong Kong well ahead of schedule, expanding its footprint across key global markets. This milestone complements recent clearances in the US, Canada, and Asia, positioning the company for significant growth in a multi-billion-dollar market.

Jameson Resources has released a comprehensive update on its Crown Mountain steelmaking coal project, revealing improved project economics and robust progress on environmental and Indigenous engagement fronts. The update underscores the project's strategic positioning amid tightening global supply and supportive government policies.

PEXA Group’s third-quarter results align with expectations, driven by Australian growth and UK market headwinds. The company reaffirms its FY25 guidance while navigating ongoing business assessments and regulatory milestones.

VHM Limited has launched a partially underwritten equity placement and share purchase plan to fund the development of its Goschen rare earths and mineral sands project, targeting production by late 2026.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Silex Systems reports steady progress on its TRL-6 uranium enrichment demonstration, targeting completion by end-2025, while securing initial US government funding to support commercialisation efforts.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.